BridgeMD
New treatment option for Acute Exacerbation of COPD
Official title Use of MULTIplex PCR, Procalcitonin, and Sputum Appearance to Reduce Duration of Antibiotic Therapy During Severe COPD EXAcerbation: A Controlled, Randomized, Open-label, Parallel-Group, Multicenter Trial
ClinicalTrials.gov ID: NCT05280132
What this study is testing
- What it's testing
- COPD is a common chronic disease. Its natural course is characterized by Acute exacerbations (AE).
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥ 18 years old
- COPD (according to GOLD 2020), whatever the stage (I-IV)
- Acute exacerbation (defined as the onset or worsening of one or more of the usual signs/symptoms of COPD) with acute worsening of respiratory...
- Informed consent of patient, patient's immediate family/ or inclusion in an emergency situation
- Affiliation to a social security
You likely can't join if
- The interval between admission to the hospital and admission to ICU more than 3 days
- Antibiotic therapy clearly needed for a suspected or documented extra-respiratory infection
- Congenital or acquired immunosuppression (congenital immune deficiency, high-grade hematologic malignancies, use of immunosuppressive drugs in the...
- Tracheotomy
- Bronchiectasis / cystic fibrosis
- Moribund patient (imminent death)
See the full eligibility criteria
- Age ≥ 18 years old
- COPD (according to GOLD 2020), whatever the stage (I-IV)
- Acute exacerbation (defined as the onset or worsening of one or more of the usual signs/symptoms of COPD) with acute worsening of respiratory symptoms that result in additional therapy) with acute respiratory failure...
- Informed consent of patient, patient's immediate family/ or inclusion in an emergency situation
- Affiliation to a social security
- The interval between admission to the hospital and admission to ICU more than 3 days
- Antibiotic therapy clearly needed for a suspected or documented extra-respiratory infection
- Congenital or acquired immunosuppression (congenital immune deficiency, high-grade hematologic malignancies, use of immunosuppressive drugs in the last 30 days including anti-cancer chemotherapy and antirejection...
- Tracheotomy
- Bronchiectasis / cystic fibrosis
- Moribund patient (imminent death)
- Patient deprived of liberty and / or under legal protection measure
- Patient already included in MULTI-EXA
- Patient already included in a type 1 treatment study on antibiotics
- Ongoing pregnancy
The study team makes the final eligibility decision.
Where it's taking place
- Paris, France
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Paris, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.